Zevra Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Neil F. McFarlane
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 101 Federal Street Boston MA United States of America 02110
- IPO Date
- Apr 16, 2015
- CIK
- 0001434647
- Website
- zevra.com
- Similar Companies
- Business
- Zevra Therapeutics, Inc. (Nasdaq: ZVRA) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company offers MIPLYFFA (arimoclomol) capsules approved in the U.S. for use in combination with miglustat to treat neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged two years and older; OLPRUVA (sodium phenylbutyrate) for oral suspension approved in the U.S. for treating certain urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS); and receives royalties and milestones from its partner Corium Inc. on AZSTARYS (serdexmethylphenidate and dexmethylphenidate), approved in the U.S. for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. Zevra maintains a late-stage clinical pipeline targeting additional rare disease indications and operates primarily in the United States with plans for European expansion of MIPLYFFA. Founded in 2006 and headquartered in Celebration, Florida, Zevra previously operated as KemPharm, Inc. before rebranding. The company targets patients with rare neurological, metabolic, and neuropsychiatric conditions through data-driven development, regulatory strategies, and commercialization efforts in collaboration with physicians, advocacy groups, and patient communities. Recent developments include the 2023 acquisition of Acer Therapeutics, which added OLPRUVA and expanded clinical assets such as Edsivo for vascular Ehlers-Danlos syndrome; U.S. FDA approval of MIPLYFFA in 2024 with ongoing commercial launches showing strong prescription uptake and market access progress; and the February 2025 sale of a Rare Pediatric Disease Priority Review Voucher for $150 million in non-dilutive proceeds to support pipeline advancement and launches. In May 2025, Zevra partnered with Alucio to deploy the Beacon platform for enhancing medical affairs scientific exchange amid its product launches. Zevra reports sequential revenue growth from MIPLYFFA and OLPRUVA, with U.S. market access reaching 66% for MIPLYFFA and European opportunities under evaluation.
Company News
Zevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zevra Therapeutics (ZVRA)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law